SEOUL: Taking a major step toward achieving vaccine sovereignty to fight against the pandemic, South Korea on Wednesday approved the use of "SKYCovione", the nation's first indigenous COVID-19 vaccine created by SK Bioscience Company.
Following an "item approval" recommendation from the MFDS' Central Pharmaceutical Affairs Council on Monday, the Ministry of Food and Drug Safety (MFDS) said it approved the use of SKYCovione, also known as GBP510, through discussions with the ministry's Final Inspection Committee, as per reports.
The first homegrown vaccine in the country to successfully complete each of its three clinical testing phases is SKYCovione. A phase-three clinical trial involving 4,000 individuals was carried out by SK Bioscience in Thailand, Vietnam, New Zealand, Ukraine, the Philippines, and South Korea.
It is a unique two-component nanoparticle-based recombinant-protein vaccination that can enhance the immune response. It was created in collaboration with the University of Washington's Institute for Protein Design. The vaccine is intended to be administered in two doses separated by four weeks.
HYD-based Biological-E to be an additional Mfg site for J&J Covid-19 Vaccine
Covacin is safe for children between 2 and 18 years, claims Bharat Biotech